Search clinical trials for: activated recombinant human factor VII

Total 6053 results

American Scitech International
Johnson & Johnson

Unknown

Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns

Burns | Electric Burns

United States
Mylan Inc.
Mylan GmbH

Completed

Efficacy and Safety Study With MYL-1401H and Neulasta

Breast Neoplasms | Chemotherapy-Induced Febrile Neutropenia

Bulgaria, Georgia, Germany, Hungary, Poland, Ukraine
University of Miami
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effects of Human Leptin Replacement

Obesity | Diabetes | Metabolic Syndrome

United States
Daiichi Sankyo, Inc.

Completed

Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

Heart Failure, Congestive | Heart Decompensation | Left Ventricular Failure | Myocardiopathies | Systolic or Diastolic Left Ventricular Dysfunction

United States, Canada
Genzyme, a Sanofi Company

Completed

High Dose or High Dose Frequency Study of Alglucosidase Alfa

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase Deficiency

United States, Canada, Australia
TNO
Alloksys Life Sciences B.V.

Completed

Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)

Healthy

Netherlands
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

Haemophilia A

Poland
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
St. James's Hospital, Ireland
Baxter BioScience

Unknown

Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens (PERSONAL)

Severe Haemophilia A

Ireland
Tasly Biopharmaceuticals Co., Ltd.

Completed

Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

Acute Ischaemic Stroke

China
Baxalta now part of Shire

No longer available

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Acquired Hemophilia A

United States
rEVO Biologics

Completed

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (rhFVIIa)

Hemophilia

Netherlands, United States
Second Affiliated Hospital, School of Medicine,...
Shanghai Weike Biopharmaceutical Co., Ltd.

Recruiting

Hyperthermic Intraperitoneal Treatment of rmhTNF for CRCPM: Phase II Clinical Trial

Colorectal Cancer | Peritoneal Metastases

China
M.D. Anderson Cancer Center
Amgen

Terminated

Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

Acute Graft Versus Host Disease

United States
CSL Behring
Parexel

Completed

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Von Willebrand Disease

Bulgaria, Poland, Russian Federation, Ukraine
Baxalta now part of Shire

Completed

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Von Willebrand Disease

United States, Germany, United Kingdom, Italy, Austria, Canada
University College, London

Recruiting

Nebulised Rt-PA for ARDS Due to COVID-19 (PACA)

COVID

United Kingdom
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

Hemophilia A

United States, Canada, Italy, Australia, Austria, Belgium, Brazil, France, Germany, Hong Kong, India, Ireland, Israel, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Kyoto University, Graduate School of Medicine

Unknown

Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure

Liver Failure, Acute

Japan
Shire

Completed

Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase

Gaucher Disease

United States, Israel, United Kingdom, Poland, Spain
Shire

Completed

A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

Gaucher Disease, Type 1

Israel, Paraguay, Argentina, Russian Federation, Tunisia
Chinese PLA General Hospital

Unknown

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

Acute Myeloid Leukemia, in Relapsed or Refractory | Acute Myeloid Leukemia, Elderly, Unfit | Acute Myeloid Leukemia With Positive Minimal Residual Disease

China
The First Affiliated Hospital of Dalian Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chinese... and other collaborators

Recruiting

Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury (Circular)

Cancer Treatment Induced Thrombocytopenia

China
Shire

Completed

Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

Late Infantile Metachromatic Leukodystrophy

Denmark
Asahi Kasei Pharma America Corporation

Completed

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Severe Sepsis | Coagulopathy

Korea, Republic of, United States, Taiwan, Netherlands, United Kingdom, Australia, Canada, Belgium, Israel, Spain, New Zealand, France, Brazil, India, Argentina, Bulgaria, Croatia, Czechia, Finland, Germany, Hungary, Peru, Russian Federation and more
BioMarin Pharmaceutical

Completed

BMN 110 Phase 3B in Australian Patients (MOR-AUS)

Mucopolysaccharidosis IVA (Morquio A Syndrome)

Australia
Asahi Kasei Pharma America Corporation

Withdrawn

The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy (Scarlet2)

Sepsis and Coagulopathy
AB2 Bio Ltd.

Completed

Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease

Still's Disease, Adult-Onset

Germany, France, Switzerland
Protalix

Completed

An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112

Gaucher Disease

Israel
CSL Behring

Completed

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

Blood Coagulation Disorders | Blood Platelet Disorders | Hematologic Disease | Von Willebrand Disease

United States
Dompé Farmaceutici S.p.A

Completed

Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. (REPARO)

Keratitis | Neurotrophic Keratitis | Corneal Ulcer

Germany, Italy, France, Poland, Spain, United Kingdom
Sichuan Clover Biopharmaceuticals, Inc.

Terminated

A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis

Peritoneal Carcinomatosis

China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

Malignant Pleural Effusions

Australia
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

BAX 855 PK-guided Dosing (PROPEL)

Hemophilia A

Spain, United States, Australia, Singapore, Taiwan, Hong Kong, Malaysia, Bulgaria, United Kingdom, Switzerland, Ukraine, Turkey, Italy, Norway, France, Austria, Romania, Sweden, Poland, Germany, Hungary, Israel
Bayer

Active, not recruiting

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Hemophilia A

Japan
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Hemophilia A

United States, France, Austria, United Kingdom, Germany, Belgium, Canada, Italy, Sweden
Sinocelltech Ltd.

Recruiting

A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

HPV Infection Vaccine Safety SCT1000

China
Zhejiang Cancer Hospital

Not yet recruiting

H101 Combined With Camrelizumab for Recurrent Cervical Cancer

Uterine Cervical Neoplasms | Oncolytic Virotherapy | Camrelizumab

China
Institute of Hematology & Blood Diseases Hospital...
Xijing Hospital; Xi'an Central Hospital; The Second Hospital of Hebei Medical... and other collaborators

Active, not recruiting

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (TE-ITP)

Previously Treated Primary Immune Thrombocytopenia

China
BioAegis Therapeutics Inc.

Completed

Rhu-pGSN for Severe Covid-19 Pneumonia

Sars-CoV2

Romania, Spain
GeneScience Pharmaceuticals Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaborators

Active, not recruiting

A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

Dwarfism

China
Sichuan Clover Biopharmaceuticals, Inc.

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

Malignant Ascites

China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

Peritoneal Malignancies

Australia
Merck Sharp & Dohme LLC

Completed

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Measles | Rubella | Mumps | Varicella
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
The First Hospital of Jilin University

Completed

Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.

Ascites

China
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Clear Cell Tumor | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian... and other conditions
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy

HIV Infections | Peripheral Nervous System Disease

United States
Amgen

Completed

Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy

Stomatitis

Search clinical trials for: activated recombinant human factor VII

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations